Dr. Hoenle AG (HNL) AI Stock Analysis

• Market Cap: €55.16M
• Dividend Yield: N/A
• Average Volume (3M): 2.33K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.85
• Revenue Growth: -3.11%
• EPS Growth: 9.59%
• Country: DE
• Employees: 585
• Sector: Industrials
• Sector Strength: 92
• Industry: Electrical Equipment & Parts
• EPS (TTM): 0.03
• Shares Outstanding: 6,062,930
• 10 Day Avg. Volume: 3,408
• 30 Day Avg. Volume: 2,330
• PEG Ratio: -0.52
• Price to Book (P/B): 3.06
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -117.07
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €10.00
• Price Target Upside: 7.99% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 43 Neutral
• Price Target: €9.00 ▼(-2.81%Downside)

The overall stock score for Dr. Hoenle AG is primarily driven by financial performance challenges, with declining revenues and high reliance on debt. The bearish technical indicators contribute to a negative sentiment. Valuation is also unfavorable, with a negative P/E ratio and no dividend yield. These factors collectively influence the low score.

Dr. Hoenle AG Business Overview & Revenue Model

Company Description

Dr. Hönle AG supplies industrial UV technologies and systems in Germany and internationally. The company operates through three segments: Adhesives, Equipment & Systems, and Glass & Lamps. The Adhesives segment provides industrial adhesives for applications, such as consumer electronics, medical technology, optics and opto electronics, automotive, and glass processing. The Equipment & Systems segment engages in the drying of inks and coatings, curing of adhesives and plastics, disinfecting surfaces, and solar simulation. The Glass & Lamps segment offers quartz glass tubing and rods for the lamp, automotive, semiconductor, and fibre cable industries, as well as lamps for water disinfection, and the drying of coatings and adhesives. The company was founded in 1976 and is headquartered in Munich, Germany.

How the Company Makes Money

Dr. Hoenle AG generates revenue through the sale of its UV technology products and services. The company's key revenue streams include the manufacturing and distribution of UV curing systems, UV lamps, and accessories, which are essential for various industrial processes. Additionally, Dr. Hoenle AG earns from offering customized solutions and after-sales services. Significant partnerships with industries such as automotive, electronics, and healthcare further contribute to its earnings by expanding its market reach and driving demand for its advanced UV technologies.

Dr. Hoenle AG Financial Statement Overview

Summary

Dr. Hoenle AG faces significant financial challenges, with declining revenues and profitability issues impacting overall performance. The balance sheet reveals a dependence on debt, while cash flows show some positive trends but remain volatile.

Income Statement

Dr. Hoenle AG's revenue has declined over recent periods, with a negative revenue growth rate from 2023 to 2024. The company has been consistently reporting net losses, reflected in a negative net profit margin and EBIT margin for the TTM. Both gross and EBITDA margins are under pressure, indicating profitability challenges.

Balance Sheet

The balance sheet shows a moderately high debt-to-equity ratio, indicating a reliance on debt financing. The return on equity is negative due to net losses, which poses a risk. However, the equity ratio remains relatively stable, suggesting a reasonable proportion of equity financing.

Cash Flow

The company has shown some improvement in free cash flow, moving from negative to positive territory. The operating cash flow to net income ratio is positive, indicating cash generation despite net losses. However, the free cash flow growth is inconsistent, highlighting volatility in cash management.

Breakdown	TTM	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	96.35M	98.73M	106.34M	116.09M	115.17M	93.88M
Gross Profit	57.62M	57.99M	53.35M	69.28M	69.34M	60.54M
EBITDA	3.58M	3.07M	779.00K	20.41M	14.02M	14.82M
Net Income	-12.96M	-13.28M	-11.01M	-13.36M	-4.82M	5.68M
Balance Sheet
Total Assets	153.47M	155.38M	176.16M	195.46M	202.91M	196.20M
Cash, Cash Equivalents and Short-Term Investments	7.47M	7.51M	9.32M	7.13M	12.07M	34.17M
Total Debt	54.23M	53.24M	56.89M	59.53M	53.64M	46.41M
Total Liabilities	74.28M	75.70M	80.02M	88.22M	91.78M	79.51M
Stockholders Equity	78.91M	79.42M	95.82M	106.88M	110.72M	116.34M
Cash Flow
Free Cash Flow	1.42M	3.44M	209.00K	-11.71M	-15.96M	-22.96M
Operating Cash Flow	3.59M	5.53M	3.14M	-7.41M	1.13M	7.23M
Investing Cash Flow	-2.04M	-2.37M	2.65M	-1.69M	-24.50M	-30.74M
Financing Cash Flow	-2.64M	-4.90M	-3.42M	3.73M	1.25M	43.25M

Dr. Hoenle AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 9.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:HNL, the sentiment is Negative. The current price of 9.26 is below the 20-day moving average (MA) of 9.50, below the 50-day MA of 9.84, and above the 200-day MA of 9.25, indicating a neutral trend. The MACD of -0.16 indicates Positive momentum. The RSI at 41.41 is Neutral, neither overbought nor oversold. The STOCH value of 23.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:HNL.

Dr. Hoenle AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	65 Neutral	$10.89B	15.56	5.22%	1.87%	3.09%	-26.84%
HNL	43 Neutral	€55.16M	―	-14.99%	―	-3.11%	9.59%
0N2B		€50.84M	21.26	-5.76%	―	―	―
0P5F		€39.26M	―		―	―	―
0FWF		€35.29M	5.36	8.05%	―	―	―
TSS		€72.25M	11.86	6.79%	5.30%	―	―
ALXA		€56.16M	11.95	18.83%	6.41%	―	―

Dr. Hoenle AG Corporate Events

Dr. Hönle AG Voting Rights Update: Stake Reduction

Dr. Hönle AG, based in Gilching, Germany, announced a change in voting rights, with FundPartner Solutions (Europe) S.A. reducing its stake from 3.19% to 2.99% of voting rights attached to shares. This adjustment reflects a disposal of shares impacting the company’s shareholding structure, potentially influencing its strategic decisions and shareholder dynamics.

Dr. Hönle AG Reports Decrease in Voting Rights

Dr. Hönle AG, based in Gilching, Germany, has announced a change in its voting rights structure. The company’s voting rights, held indirectly through shares, have decreased from 3.19% to 2.99%, as reported by Quaero Capital S.A. This reduction may influence the company’s governance and stakeholder dynamics.

Dr. Hönle AG Reports Change in Voting Rights

Dr. Hönle AG, a company based in Gilching, Germany, has announced a change in its voting rights, reflecting a decrease in the shareholding threshold. As of February 7, 2025, Quaero Capital Funds (Lux), based in Luxembourg, has reduced its voting rights in Dr. Hönle AG from 3.19% to 2.99%, which translates to 181,531 voting rights. This shift in shareholder voting rights indicates a strategic adjustment in ownership stakes for stakeholders involved.